The Medipattern Corporation

The Medipattern Corporation

June 24, 2008 06:30 ET

Medipattern Receives Frost and Sullivan 2008 Best Practices Award

Medipattern's proactive approach to managing patient risk cited as key customer value

TORONTO, ONTARIO--(Marketwire - June 24, 2008) -

Attention: Business/Financial Editors:

The Medipattern Corporation (TSX VENTURE:MKI), an award-winning developer of computer-aided detection (CAD) medical imaging software designed to aid physicians in making better risk management decisions permitting a higher standard of care for the millions of patients at risk of cancer, is pleased to announce that it has been awarded one of Frost and Sullivan's coveted Best Practices Awards. The 2008 North American Breast Imaging Customer Value Enhancement Award has been awarded to Medipattern for its

- proactive approach in partnering with the medical community to create a solid product

- unique product approach using the ACR BI-RADS® lexicon as a quality standard tool to describe and classify lesions

- enhanced customer support by offering pre-sales, sales and continued support with access to CME training classes and further expert encounters

The award citation concludes:

Medipattern provides significant value to the medical community and the patient by going beyond technological expertise, to provide superb, high-quality product support and customer education programs. Keeping in mind that X-ray mammography is approximately only 50 percent effective in detecting lesions on women with dense breasts, the B-CAD™ software in conjunction with ultrasound enables a concise and efficient reading of imaging data for these women, enhancing value on both sides of the spectrum.

"Medipattern meets the needs of patients and clinicians by maintaining a strong focus on early detection by offering a technology and an ensemble of associated services that enable a systematic approach to breast imaging," states Frost & Sullivan Research Analyst Samantha Barbosa. "Medipattern's offering includes access to education, increasing knowledge and skill set as well as standardizing communication through the American College of Radiology BI-RADS® lexicon and methodology which in turn raises the quality standards for participating medical facilities, as well as the standard of care for the millions of patients served by breast ultrasound imaging."

"Medipattern is honoured to be recognized by Frost and Sullivan, a growth partnership company and the industry recognized leader in tracking the healthcare market sector. From its unique perspective, Frost and Sullivan identifies the best technologies, developers and manufacturers of healthcare products," states Jeff Collins, CEO of The Medipattern Corporation. "Receiving the Best Practices Award is especially significant to us, since it is the first time that a CAD developer has been granted this award."

"B-CAD™ is the first detection and risk management tool affirming the physician's decisions, consistently documenting the diagnosis in a thorough and organized process, reinforcing standardization of care. Our customizable electronic worksheet, also an industry first, communicates the sonographer's findings with access to breast sonography training and education. Our training programs supporting breast ultrasound have been well received from the UK to China, in the USA and here in Canada. We decided to formalize the program as B-CAD University (B-CAD U). World-renowned lecturer, Cindy Rapp, Vice President of Clinical Program Development from Medipattern, hosts B-CAD U with other faculty members from Medipattern's medical advisory board. B-CAD U will start regularly scheduled events in September which will include hands-on training, lectures, as well as interactive web question and answer sessions where the B-CAD community can receive expert guidance on imaging, image management, as well as patient risk management questions."

About Frost and Sullivan

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit

The Medipattern Corporation

Medipattern develops computer-aided detection (CAD) solutions for medical imaging. These products enhance workflow while improving interpretive and diagnostic confidence. The Company's initial clinical applications are B-CAD™ for breast ultrasound and B-CADMRI™. Both have received awards for innovation in the industry. The Company's CADENZA™ platform products use pattern recognition technology to assist radiologists in their efforts to classify and characterize medical images. Please visit the company's website at:

Upcoming Events:

Medipattern will participate in the following events:

- Chicago International Breast Course, September 11 to 14, Chicago, IL, USA

- Radiological Society of North America (RSNA), November 30 to December 5, Chicago, IL, USA

B-CAD™ and B-CADMRI™ are trademarks of The Medipattern Corporation.
Medipattern® is a registered mark of The Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.

Contact Information